UNSPSC 51171849: Levonantradol

This classification denotes an antiemetic agent with the molecular formula C27H35NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 03S640ADSK, chemically known as 1,9-phenanthridinediol, 5,6,6a,7,8,9,10,10a-octahydro-6-methyl-3-((1r)-1-methyl-4-phenylbutoxy)-, 1-acetate, (6s,6ar,9r,10ar)- but generally known as levonantradol, which bears US NIH Compound Identifier 5361881. European Medicines Agency schedules Levonantradol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08482MIG.

UNSPSC 51171849 Levonantradol is a Commodity code that appears in state and local solicitations primarily for drug testing and pharmaceutical procurement, though the recent opportunities show limited direct purchasing of levonantradol itself. Instead, issuing bodies are using the code to tag broader drug-testing services and generic pharmaceutical supply agreements where confirmation testing methodologies (including LC/MS/MS and GC/MS) would detect controlled substances and their metabolites. State and local governments soliciting under this code include county criminal-justice departments (community supervision and corrections), state health and human services agencies, and cooperative purchasing alliances serving multi-state public-sector networks. Collin County Community Supervision and Corrections Department, for example, posted RFP 2026-327 on July 9, 2026, requesting offender specimen collection and drug testing services with a response deadline of July 23, 2026; the county is seeking a vendor to staff two testing sites in the Dallas-Fort Worth area, operate randomized testing notifications, conduct five-panel and six-panel immunoassay screening with LC/MS/MS or GC/MS confirmation, and provide alternative testing methodologies including oral fluid and hair analysis, with an estimated contract value of $600,000 over two years and three optional one-year renewal periods.

Recent activity concentrates in Texas and Minnesota. Collin County's July 2026 RFP reflects Texas criminal-justice demand; the Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to explore direct-to-manufacturer pharmaceutical prescribing models, though that inquiry is preliminary market intelligence and does not commit to specific purchasing volumes. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026, with proposals due March 26, 2026, to establish contracts for generic multi-source pharmaceuticals and OTC products distributed to state and local government facilities across Minnesota and Oregon through three authorized wholesalers, with contract awards effective July 1, 2026. The code shows mixed recent activity — strong signal in criminal-justice drug testing in Texas, exploratory pharmaceutical procurement in Texas HHS, and multi-state generic pharmaceutical contracting in the Upper Midwest.